Arca
Skip to content
Tools
Tools

Warning Letter to Mitra Distributing Inc.

Unspecified. See Mitra Distributing's company page or this site's inspections.

On Sep 4, 2018, FDA's CDER sent Mitra Distributing Inc. a warning letter citing unapproved new drug, marketing claims, labeling.

  • Letter date: Sep 4, 2018
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

• “Kratom can render both mildly stimulating effects and mildly relaxing effects depending upon the measurement used. At smaller amounts, the effects tend to be slightly more stimulating; and at larger amounts, the effects tend to be more relaxing. ”

• “Some [kratom users] have reported an increase in focus, attentiveness, and social confidence resulting from the responsible use of kratom.”

• “Due to the rise in opium costs and the discovery that kratom could relieve opium withdrawals, many users turned to kratom as a means to cure their addiction.”

• “It has been long reported that kratom has been used to treat a myriad of ailments including but not limited to: diarrhea, depression, diabetes, obesity, high blood pressure, stomach parasites, diverticulitis, anxiety, alcoholism, and opiate withdrawal.”

• “One way to avoid the synthetic roller coaster of addiction is to opt for a natural alternative – kratom. Kratom has been used for hundreds of years to promote opiate withdrawal relief in Southeast Asia and is quickly gaining popularity in the United States. With the rate of opiate use on the rise, people need as many options available to them as possible when battling addiction. Learn more about kratom and how it can be the solution to promoting an opiate free lifestyle by visiting our About Kratom page”

• “[I]s there a better way? Yes there is – kratom. Kratom has been used for hundreds of years to help eliminate withdrawal symptoms from opiates of all kinds. Kratom has been used to treat everything from mild pain pill addiction to heroin addiction.”

Recent Letters Citing Unapproved new drug

See them all

Record

Recipient
Christopher Marion
FDA site ID (FEI)
3014654355

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.